تحقیق و توسعه

هموگلوبینوپاتی ها

Research

Ind-Enabling

Clinical

Approved

Description: Investigational allogeneic CRISPR/Cas9 gene-edited CAR T cell therapy in development for the treatment of CD19+ malignancies and autoimmune diseases that incorporates novel edits designed to enhance CAR T potency and reduce CAR T exhaustion

Structure: Wholly owned

* Exagamglogene Autotemcel (exa-cel): Sickle cell disease (SCD)

Description: Investigational allogeneic CRISPR/Cas9 gene-edited CAR T cell therapy in development for the treatment of CD19+ malignancies and autoimmune diseases that incorporates novel edits designed to enhance CAR T potency and reduce CAR T exhaustion

Structure: Wholly owned

* Exagamglogene Autotemcel (exa-cel): Sickle cell disease (SCD)

Description: Investigational allogeneic CRISPR/Cas9 gene-edited CAR T cell therapy in development for the treatment of CD19+ malignancies and autoimmune diseases that incorporates novel edits designed to enhance CAR T potency and reduce CAR T exhaustion

Structure: Wholly owned

* Exagamglogene Autotemcel (exa-cel): Sickle cell disease (SCD)

Description: Investigational allogeneic CRISPR/Cas9 gene-edited CAR T cell therapy in development for the treatment of CD19+ malignancies and autoimmune diseases that incorporates novel edits designed to enhance CAR T potency and reduce CAR T exhaustion

Structure: Wholly owned

* Exagamglogene Autotemcel (exa-cel): Sickle cell disease (SCD)

ایمونوآنکولوژی و بیماری خودایمنی

Research

Ind-Enabling

Clinical

Approved

Description: Investigational allogeneic CRISPR/Cas9 gene-edited CAR T cell therapy in development for the treatment of CD19+ malignancies and autoimmune diseases that incorporates novel edits designed to enhance CAR T potency and reduce CAR T exhaustion

Structure: Wholly owned

* Exagamglogene Autotemcel (exa-cel): Sickle cell disease (SCD)

Description: Investigational allogeneic CRISPR/Cas9 gene-edited CAR T cell therapy in development for the treatment of CD19+ malignancies and autoimmune diseases that incorporates novel edits designed to enhance CAR T potency and reduce CAR T exhaustion

Structure: Wholly owned

* Exagamglogene Autotemcel (exa-cel): Sickle cell disease (SCD)

Description: Investigational allogeneic CRISPR/Cas9 gene-edited CAR T cell therapy in development for the treatment of CD19+ malignancies and autoimmune diseases that incorporates novel edits designed to enhance CAR T potency and reduce CAR T exhaustion

Structure: Wholly owned

* Exagamglogene Autotemcel (exa-cel): Sickle cell disease (SCD)

Description: Investigational allogeneic CRISPR/Cas9 gene-edited CAR T cell therapy in development for the treatment of CD19+ malignancies and autoimmune diseases that incorporates novel edits designed to enhance CAR T potency and reduce CAR T exhaustion

Structure: Wholly owned

* Exagamglogene Autotemcel (exa-cel): Sickle cell disease (SCD)